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Introduction: Pilot trials are initial small-scale studies done to inform the design of larger trials. Their ﬁndings
like other studies are usually disseminated as peer-reviewed journal articles. Abstracts are used to introduce the
contents to readers, and give a general idea about the full reports and sometimes are the only source of in-
formation available to readers. Despite their importance, the contents of abstracts of trial reports are usually not
informative enough and lack the essential details.
Methods and analysis: This is a protocol for a planned systematic survey with a primary aim of analyzing the
reporting quality measured as the completeness of the reporting of pilot trial abstracts in heart failure. The
secondary aim will be to explore factors associated with better reporting quality.
Abstracts of heart failure pilot trials in humans (journal and conference abstracts) published in the English
language from 1 January 1990 to 30 November 2016 will be assessed to determine the reporting quality, based
on the CONSORT 2010 statement extension to randomized pilot and feasibility trials. All non-pilot/feasibility
trials and non-human pilot trials will be excluded. We will search Medline (PUBMED), Cochrane controlled trials
register, Scopus and African wide information databases for pilot trials in heart failure. Title and abstracts of
identiﬁed studies will be screened for inclusion and data extracted independently by two reviewers in duplicate
without using the full text. Reported and unreported items on the abstracts will be presented as frequencies and
percentages, a descriptive analysis will be used to interpret the reporting quality and regression analysis used for
characteristics associated with greater statistical reporting at 95% conﬁdence interval.
Review registration number: PROSPERO CRD42016049911.
1. Introduction
Abstracts are introductory summaries of full text that provide
readers with a quick overview of the contents of the papers. They serve
as an important aid in knowledge dissemination. Many researchers rely
on abstracts as a concise source of information [1], helping them follow
developments in the literature [2] and in reaching decisions on what
articles to read in detail. Reasons advanced for the essential role of
abstracts include the challenge of the large volume of literature, un-
availability/inaccessibility of full text to some readers due to high cost
[3,4], and the fact that some articles not published in English provide
abstracts in English to reach a wider audience. These important roles of
abstracts, therefore, require that they contain suﬃcient and accurate
information that will guild the readers into contents of the full text [5].
Pilot trials refer to initial small studies that researchers use in
reaching the decision on commencing larger conﬁrmatory trials [6–8].
They are comprised of a distinctive group of randomized controlled
trials (RCT) often referred to as pilot and feasibility trials which do not
have eﬀectiveness or eﬃcacy as their primary focus [9]. By the nature
of their design, they are not powered for hypothesis testing, but rather
should emphasize on conﬁdence interval estimation and are usually
designed to support the development of a future deﬁnitive RCT.
The consolidated standard for reporting of trials (CONSORT)
statement (www.consort-statement.org) originated because of the
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concern raised over the years on the quality of report of RCTs [10]. It is
a guideline that was designed to improve the quality of reporting, ﬁrst
published in 1996 revised in 2001 and later updated in 2010 [11,12], to
address this observation by providing a benchmark for complete re-
porting of trials. This development has been well received by many peer
review journals [13] and has been shown to improve the quality of
reporting of trials [14–16].
The noted improvement has led to the extension of the checklist to
various other forms of trials such as non-inferiority, equivalence, and
cluster or pragmatic designs. There have also been extensions for dif-
ferent types of interventions (non-drug treatments and herbal inter-
ventions), Patient-reported outcomes, as well as extensions for re-
porting harms. One major characteristic of the main CONSORT
statement and all the current extensions is that they focus on trials for
which the research question centers on the eﬀectiveness or eﬃcacy of
an intervention. But as stated above pilot and feasibility trials are de-
signed for a diﬀerent purpose, serving as a precursor to deﬁnitive trials
and have been at various times described as a neglected arm of medical
research [17]. In order to improve reporting of pilot and feasibility
trials, a group of researchers recently developed a checklist extension to
serve this function [18].
In this paper, we present a protocol for a systematic survey of
quality of reporting in abstracts of pilot trials in heart failure, aimed at
evaluating the completeness of such reports based on the checklist ex-
tension. For the purpose of the survey, heart failure is deﬁned as a
clinical condition often referred to as congestive heart failure (CHF),
which occurs when the heart is unable to pump suﬃciently to maintain
blood ﬂow to meet the body's needs [19]. We will be reviewing ab-
stracts of journal publications and conferences focusing on all types of
heart failure. We chose heart failure for this survey because of its role in
the global burden of cardiovascular diseases [20,21] and the large vo-
lumes of trials in heart failure.
In the last two decades, an increasing number of clinical trials in
cardiovascular disease (CVD) have been conducted mainly due to the
rising prominence of CVD as one of the leading causes of morbidity and
mortality [21]. A sizable number of these clinical studies were preceded
by pilot trials and their results disseminated to the public through
publications. However, these pilot studies were not exempt from the
inconsistency in quality reporting of most of the randomized control
trials (RCT). The quality of reporting across journals is variable with
some journal abstracts communicating adequate information and some
grossly insuﬃcient for accurate interpretation [22]. The correct inter-
pretation of abstracts can be enhanced if the reporting of the study
design, methods, and results are complete and uniform across journals
[23,24]. Similarly, a structured and detailed reporting of RCT helps
guideline developers and policy makers as they rely on RCTs [24,25].
Incomplete information which may follow using a very small sample or
not well-deﬁned outcomes [26,27] make it diﬃcult to trust the ﬁndings
resulting in suboptimal use of these RCTs [28]. Other factors that have
also been reported to inﬂuence the quality of report of trials include
multi-center studies, trials involving pharmacological studies, industrial
sponsored studies and those reporting positive results for their primary
outcome [29]. Hence, it is imperative for authors to report complete
details of their research and for journals to ensure proper reporting is
adhered to by authors.
The primary hypothesis in the planned systematic survey is that the
quality of reports in abstracts of pilot trials in heart failure based on the
CONSORT checklist extension for pilot and feasibility trials is poor. The
exploratory hypothesis is that items in CONSORT extension for re-
porting of pilot trials will be seen more in publications that contain the
characteristics mentioned above.
2. Methods and analysis
2.1. Primary Objective
To evaluate the reporting quality of abstracts of pilot trials in heart
failure in the past 26 years (1990–2016), using CONSORT extension for
reporting of abstracts of pilot trials as the reference standard.
2.2. Secondary Objectives
1 To identify aspects of the checklist consistently reported in pilot
trials
2 To identify factors associated with proper reporting of abstracts of
pilot trials
2.3. Inclusion criteria
• Type of studies: pilot/feasibility heart failure trial with a rando-
mized control design (parallel or cluster) done in humans,
• Participants: reports on population with heart failure,
• Intervention: pharmacological and non-pharmacological interven-
tions evaluating clinical outcomes,
• Publications from 1st January 1990 to 30 November 2016.
2.4. Exclusion criteria
• Non-pilot trials in heart failure,
• Animal studies.
2.5. Study design
The proposed survey will involve a systematic review of a sample of
abstracts from all available publications on pilot trials in heart failure
published from January 1990 to November 2016. We will system-
atically search Medline (PUBMED), Cochrane controlled trial register,
Scopus, and African wide information electronic databases using search
terms and medical subject headings (MESH) to identify heart failure
pilot trials investigating pharmacological and non-pharmacological in-
terventions (Table 1 and Appendix A). Articles will be restricted to
those written in the English language.
Table 1
Medline search strategy.
(((((Heart failure[MeSH Terms]) OR ((Heart failure OR paroxysmal dyspnea OR
diastolic heart failure OR systolic heart failure OR Cardiac Failure OR Heart
Decompensation OR Myocardial Failure OR Congestive Heart Failure OR
Ventricular dysfunction OR cardiac insuﬃciency OR myocardial failure OR
myocardial insuﬃciency)))) AND ((randomized controlled trial [pt] OR
controlled clinical trial [pt] OR randomized controlled trials [mh] OR random
allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR
clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw]
OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind*
[tw])) OR (placebos [mh] OR placebo* [tw] OR random* [tw] OR research
design [mh:noexp] OR (comparative study) OR (comparative studies) OR
(evaluation studies) OR (evaluation study) OR follow-up studies [mh] OR
prospective studies [mh] OR controlled [tw]OR controls [tw]OR control [tw] OR
prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT human [mh])))))
AND (((Pilot projects[MeSH Terms]) OR Feasibility Studies[MeSH Terms]) OR
((pilot OR feasibility)))
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3. Data extraction and synthesis
Selected articles based on the key search words of pilot trials in
heart failure from 1990 to 2016 will be exported to Endnote X7® re-
ference manager software; duplicates will be identiﬁed and removed.
Screening and data abstraction will be done independently and in du-
plicate by two reviewers (GI and MZ) using a customized data extrac-
tion form in Microsoft Excel® format. Reviewer agreements will be
measured using kappa statistics [30]. Discrepancies and diﬀerences of
opinion will be resolved by consensus between reviewers or arbitration
by a third reviewer. The abstracts (both journal and conference) will be
evaluated using the 16 items of the CONSORT extension (Appendix B);
where the item combines two or more pieces of information (e.g.
eligibility and setting), each will be counted separately if it can stand
alone. Where they are open to interpretation, the reviewers' inter-
pretation of relevant information will be used. Reported items will be
checked as yes and unreported items as no. Non-applicable items will
be checked as NA. All “yes” responses will be assigned the number 1,
while “no” and NA will be assigned 0. The overall quality of the ab-
stracts will be calculated as a proportion of yes.
3.1. General characteristics
Information to extract from the publications will include names and
addresses of authors, journal names, impact factor, Journal policy on
the endorsement of CONSORT statement (by checking on the website of
the journal), year of publication.
3.2. Assessment of abstract using CONSORT extension for pilot and
feasibility trials checklist
Title identiﬁcation as trials will be checked, and abstract format
noted as structured or unstructured. Trial design (Cluster/parallel),
participant's characteristics such as eligibility and setting of pilot trial
conduct, type of intervention in each group, Single or multiple centers,
as well as deﬁned pre-speciﬁed objectives. Other things to be checked
will include pre-speciﬁed measurements to determine the outcome,
method of randomization and blinding, the number of participants
screened and randomized. There will also be an evaluation of analysis
done in each group including study outcome, explanation of harm re-
porting and general interpretation of result discussing risk and beneﬁt.
Finally, we will check the conclusions drawn from the study, implica-
tions for future deﬁnitive trial, trial registration and funding informa-
tion.
4. Deﬁnition of adequate reporting
The CONSORT extension for reporting of abstracts has 16 items
which are expected to be in an abstract. In this survey, a publication
abstract will be judged as adequate if all the items are reported.
Table 2
Estimation of sample size based on 95% Conﬁdence Interval.
P0
0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95
E 0.01 9604 9507 9219 8739 8067 7203 6147 4898 3457 1824
0.05 384 372 368 349 322 288 245 195 138 73
0.10 96 95 92 87 80 72 61 49 34 18
P0 = Prior estimate of studies with adequate reporting.
E = Margin of error for the estimate.
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4.1. Sampling scheme and sample size calculation
We will consider for inclusion in the systematic survey, all sampled
studies described as pilot or feasibility randomized control trials (RCT)
from the general sampling population of RCTs in heart failure. Eligible
trials will be those done in humans from 1 January 1990 to 30
November 2016 and reported in the English language. Nonrandomized
trials and crossover studies will not be included in the survey. For
purposes of the survey, adequate reporting of abstract will be de-
termined by considering the proportion of studies reporting up to 16
items in the checklist. Using a 95% conﬁdence interval approach, the
number of required pilot trials abstracts (n) for the survey will be given
by:
= −n P P E1.962( (1 )/ )0 0 2
where 1.96 is the z-score associated with a 95% conﬁdence interval, P0
is the prior estimate of the proportion of studies with adequate re-
porting of abstract and E is the target margin of error for the estimate.
With a margin of error of E = 0.10, our expectation is that the number
of studies with an adequate report of abstracts will be calculated at
P0 = 0.60 [31,32] (Table 2).
4.2. Statistical analyses
As shown in Table 3, the analysis will be divided into two sections.
4.2.1. Primary outcome measures
Reporting quality by presenting reported and unreported items on
the checklist as frequencies and percentages using descriptive analysis.
4.2.2. Secondary outcome measures
Negative binomial regression analysis will be used to determine the
study characteristics associated with greater statistical reporting. Count
of adequately reported items on the checklist will be the dependent
variable. The independent variable will include the following char-
acteristics linked to reporting quality in previous publications
[11,23,24,26,27,29]; journal impact factor, endorsement of CONSORT,
sample size, single or multiple sites, type of study (pharmacological or
non-pharmacological), abstract format (structured or unstructured).
Incident risk ratio (IRR) will be calculated to evaluate factors associated
with better reporting. The result will be presented as IRR with 95%
conﬁdence interval and associated p-values. The criterion for statistical
signiﬁcance will be set at alpha = 0.05. We will use SPSS software
version 23 (Chicago, IL) for all analyses.
5. Ethics and dissemination
Formal ethical approval is not required for the proposed survey as
data collection is based on publicly available reports. This protocol was
written according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis extension for Protocols (PRISMA-P) [33].
We will submit this systematic survey when completed to a peer-re-
viewed journal for publication, and the ﬁndings will also be presented
at an upcoming conference.
6. Discussion
This planned systematic survey of quality of abstracts of pilot trials
was registered prospectively in PROSPERO (CRD42016049911) and the
protocol was written in line with PRISMA-P. It is to the best of our
knowledge the ﬁrst of such review using the CONSORT extension for
reporting abstracts of pilot trials. The heart failure trials to be analyzed
were published before the introduction of the CONSORT extension.
However, the work will serve as the basis to evaluate improvement
when the extension is fully in operation.
7. Authors' data sharing and contributions
All authors contributed to the protocol and approved the ﬁnal
manuscript. LT and BM were responsible for the conception of the
survey. GI was involved in the search strategy. GI and LT designed the
survey. GI, MZ, MC were involved in designing and testing of the data
extraction form. GI wrote the initial draft, GI and LT contributed to
improvements in the manuscript and BM and LT critically revised the
ﬁnal draft.
All authors approved the ﬁnal written manuscript.
Responsibility for statistical analysis Plan: MC.
Guarantor of the systematic survey; Prof. Lehana Thabane.
8. Funding statement
This research received no speciﬁc grant from any funding agency in
the public, commercial or not-for-proﬁt sectors.
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Appendix A
Heart failure Pilot Trial Search Strategy.
PubMed search
Heart failure [Mesh] OR.
Heart failure OR paroxysmal dyspnea OR diastolic heart failure OR systolic heart failure OR Cardiac Failure OR Heart Decompensation OR
Myocardial Failure OR Congestive Heart Failure OR Ventricular dysfunction OR cardiac insuﬃciency OR myocardial failure OR myocardial in-
suﬃciency.
AND.
Filters for RCT's in PubMed courtesy University of Cape Town Library
Randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-
blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (“clinical trial” [tw]) OR ((singl* [tw] OR doubl*
[tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR (placebos [mh] OR placebo* [tw] OR random* [tw] OR research design
[mh:noexp] OR (comparative study) OR (comparative studies) OR (evaluation studies) OR (evaluation study) OR follow-up studies [mh] OR pro-
spective studies [mh] OR controlled [tw]OR controls [tw]OR control [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT human
[mh])
AND.
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Pilot projects [MeSH] OR Feasibility Studies [MeSH] OR pilot OR feasibility.
Filter by years.
Filter by years (1 January 1990–1 May 2016)
Africa-Wide (Ebsco) and Web of Science
Heart failure OR paroxysmal dyspnea OR diastolic heart failure OR systolic heart failure OR Cardiac Failure OR Heart Decompensation OR
Myocardial Failure OR Congestive Heart Failure OR Ventricular dysfunction OR cardiac insuﬃciency OR myocardial failure OR myocardial in-
suﬃciency.
AND.
Clinical trial OR randomized controlled trial OR randomized controlled trial OR random allocation OR double-blind OR single-blind OR placebo
OR random research OR comparative study OR evaluation study OR follow up OR follow-up OR prospective OR control OR volunteer OR single mask
OR double mask OR treble mask OR triple mask OR single blind OR double-blind OR treble blind OR triple blind.
AND.
Pilot OR feasibility.
Filter by years (1 January 1990–1 May 2016)
Scopus-
Heart failure OR paroxysmal dyspnea OR diastolic heart failure OR systolic heart failure OR Cardiac Failure OR Heart Decompensation OR
Myocardial Failure OR Congestive Heart Failure OR Ventricular dysfunction OR cardiac insuﬃciency OR myocardial failure OR.
Myocardial insuﬃciency.
AND
Clinical trial OR randomized controlled trial OR randomized controlled trial OR random allocation OR double-blind OR single-blind OR placebo
OR random research OR comparative study OR evaluation study OR follow up OR follow-up OR prospective OR.
Control* OR volunteer OR single mask OR double mask OR treble mask OR triple mask OR.
Single-blind OR double-blind OR treble blind OR triple blind AND pilot OR feasibility.
Appendix B. CONSORT extension for reporting abstracts of pilot trials 9
Item Extension for pilot trials Judgment Score
Yes No
Title Identiﬁcation of study as a randomized pilot trial
Trial design Description of pilot trial design (e.g. parallel, cluster
METHODS
Participants Eligibility criteria for participants and the settings where the pilot trial was conducted
Interventions Interventions intended for each group
Objective Speciﬁc objectives of the pilot trial
Outcome Pre-speciﬁed assessment or measurement to address the pilot trial objective(s)1
Randomization How participants were allocated to the interventions
Blinding (masking) Whether or not participants, caregivers, and those assessing the outcomes were blinded to group
assignment
RESULTS
Numbers
randomized
Number of participants screened and randomized to each group for the pilot trial objective(s)1
Recruitment Trial status2
Numbers analyzed Number of participants analyzed in each group for the pilot objective(s)1
Outcome Results for the pilot objective (s); including any expressions of uncertainty1
Harms Important adverse events or side-eﬀects
Conclusion General interpretation of the results of pilot trial and their implications for the future deﬁnitive trial
Trial registration Registration number for pilot trial and name of trial register
Funding Source of funding for pilot trial
1 Space permitting, list all pilot trial objectives and give the results for each. Otherwise, report those, which are a priori, agreed as the most important (main) to the decision to proceed
with the future deﬁnitive trial.
2 For conference abstracts.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.conctc.2017.11.004.
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